Gliosarcoma

• CLINICAL_TRIALS withdrawal · 2025-05-07
  Clinical Trial Update: Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy [Phase 1]

  A Phase 1 trial evaluating a combination of temozolomide, memantine hydrochloride, mefloquine, and metformin hydrochloride in glioblastoma m…

• EMA withdrawal · 2022-06-17
  EMA Application withdrawn: Sitoiganap (allogeneic glioma tumor cell lysates (inactivated);allogeneic glioma tumor cells (inactivated);autologous glioma tumor cell lysates (inactivated);autologous glioma tumor cells (inactivated)) — Epitopoietic Research Corporation-Belgium (E.R.C.)

  The EMA has withdrawn the application for Sitoiganap, an immunotherapy consisting of inactivated allogeneic/autologous glioma tumor cell lys…

• CLINICAL_TRIALS withdrawal · 2018-07-19
  Clinical Trial Update: Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma [Phase 1]

  A Phase 1 clinical trial evaluating a nasal spray for recurrent glioblastoma and related gliomas has been withdrawn.

• CLINICAL_TRIALS withdrawal · 2016-02-15
  Clinical Trial Update: EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma [Phase 1, Phase 2]

  A Phase 1/Phase 2 trial evaluating EGFRBi-armed autologous T cells for adult brain glioblastoma and gliosarcoma has been withdrawn.

• CLINICAL_TRIALS withdrawal · 2015-11-06
  Clinical Trial Update: Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma [Phase 2]

  A Phase II trial evaluating sorafenib with radiation and temozolomide for newly diagnosed glioblastoma or gliosarcoma was withdrawn.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS withdrawal · 2014-06-02
  Clinical Trial Update: Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas [Phase 1]

  Phase 1 trial evaluating genetically modified stem cells with Irinotecan hydrochloride for recurrent high-grade gliomas has been withdrawn.

• CLINICAL_TRIALS withdrawal · 2012-11-21
  Clinical Trial Update: Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma [Phase 1]

  A Phase I trial of dasatinib in combination with protracted temozolomide for recurrent malignant glioma has been withdrawn.